Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Gasser R, Ablasser K, Roessl U, Kraigher-Krainer E, Lewinski D, Mangge H, Mächler H, Trantina-Yates A, Tscheliessnigg KH, Udermann H, Porta S, Friehs I, Scherr E, Brussee H, Gasser S
Differential Gene Expression und Nebivolol and Atenolol during Experimental Ischemia in Human Myocardium
Journal of Clinical and Basic Cardiology 2008; 11 (1-4): 16-23

PDF    Summary    Overview   

First Image Fig. 4: Nebivolol - Atenolol Fig. 5: Nebivolol - Atenolol Fig. 6: Biochemical process Fig. 7: Well-oxygenized preparations Fig. 8: Gene expression Fig. 9: Biological Pathways This Image - Fig. 10: Pathway - Up-Regulation Fig. 11: Nebivolol - Biological Pathway
Figure/Graphic 10: Pathway - Up-Regulation
Generally, we could see that, during experimental ischemia, upregulation of pathways is minimal by nebivolol over atenolol. This becomes evident in Figure 9a, only 3 pathways are affected. However, the interleukin signalling pathway may be of interest in connection with inflammation, scarring and remodelling.
 
Pathway - Up-Regulation
Previous Image Next Image   


Figure/Graphic 10: Pathway - Up-Regulation
Generally, we could see that, during experimental ischemia, upregulation of pathways is minimal by nebivolol over atenolol. This becomes evident in Figure 9a, only 3 pathways are affected. However, the interleukin signalling pathway may be of interest in connection with inflammation, scarring and remodelling.
 
 
copyright © 2000–2025 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum
 
Werbung